Source comparison
AOD-9604 Results After 1 Week: Comparison Across Dosing Protocols
500 mcg daily subcutaneous No measurable DEXA change; possible 0.2–0.5 kg scale weight reduction (likely water/glycogen) 1.2–2.1 kg fat mass reduction in clinical cohorts; 3–6 mm subcutaneous fat thickness decrease Beta-3 receptor saturation achieved; HSL upre
This comparison does not assign a generated winner or score.
- 500 mcg daily subcutaneous
- No measurable DEXA change; possible 0.2–0.5 kg scale weight reduction (likely water/glycogen)
- 1.2–2.1 kg fat mass reduction in clinical cohorts; 3–6 mm subcutaneous fat thickness decrease
- Beta-3 receptor saturation achieved; HSL upregulation sustained; oxidative demand required for outcome
- Effective dose. Outcome lags mechanism by 3–4 weeks
- 1000 mcg daily subcutaneous
- No measurable DEXA change; subjective reports of reduced hunger (appetite suppression not a documented AOD-9604 effect)
- 1.8–3.2 kg fat mass reduction; localized abdominal fat reduction more pronounced than peripheral
- Higher dose does not accelerate week-one outcome; lipolysis rate-limited by mitochondrial oxidative capacity
- Doubling dose does not halve timeline. Same 4-week lag
- 250 mcg twice daily (split dose)
- No measurable DEXA change
- 1.0–1.6 kg fat mass reduction; slightly lower magnitude than single daily dose
- Split dosing maintains more consistent plasma levels but does not overcome oxidative bottleneck
- Marginal benefit over single daily; outcome still requires 4+ weeks
- Oral administration (experimental)
- No measurable effect; peptide degraded in GI tract before systemic absorption
- No measurable effect beyond placebo
- AOD-9604 has poor oral bioavailability. Subcutaneous or intravenous required
- Not viable. Use subcutaneous only